CRPD Frontiers in Movement Disorders Therapeutics: From Evidence to Treatment and Applications: Addressing Patients' Needs in the Management of the Ataxias

Overview

Journal Clin Park Relat Disord

Date 2024 May 27

PMID 38798918

Authors

Susan L Perlman

Affiliations

Soon will be listed here.

Abstract

The genetic ataxias have no cures and no proven ways to delay progression (no disease-modifying therapies). The acquired ataxias may have treatments that address the underlying cause and may slow or stop progression, but will not reverse damage already sustained. The idiopathic ataxias (of unknown genetic or acquired cause) also have no proven disease-modifying therapies. However, for all patients with ataxia of any cause, there is always something that can be done to improve quality of life-treat associated symptoms, provide information and resources, counsel patient and family, help with insurance and disability concerns, be available to listen and answer the many questions they will have.

References

Beaudin M, Matilla-Duenas A, Soong B, Pedroso J, Barsottini O, Mitoma H . The Classification of Autosomal Recessive Cerebellar Ataxias: a Consensus Statement from the Society for Research on the Cerebellum and Ataxias Task Force. Cerebellum. 2019; 18(6):1098-1125. PMC: 6867988. DOI: 10.1007/s12311-019-01052-2. View

Ashizawa T, Figueroa K, Perlman S, Gomez C, Wilmot G, Schmahmann J . Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study. Orphanet J Rare Dis. 2013; 8:177. PMC: 3843578. DOI: 10.1186/1750-1172-8-177. View

Barbuto S, Kuo S, Stein J . Investigating the Clinical Significance and Research Discrepancies of Balance Training in Degenerative Cerebellar Disease: A Systematic Review. Am J Phys Med Rehabil. 2020; 99(11):989-998. PMC: 8260091. DOI: 10.1097/PHM.0000000000001476. View

Lin C, Kuo S . Ataxias: Hereditary, Acquired, and Reversible Etiologies. Semin Neurol. 2023; 43(1):48-64. PMC: 10354687. DOI: 10.1055/s-0043-1763511. View

Traschutz A, Adarmes-Gomez A, Anheim M, Baets J, Brais B, Gagnon C . Responsiveness of the Scale for the Assessment and Rating of Ataxia and Natural History in 884 Recessive and Early Onset Ataxia Patients. Ann Neurol. 2023; 94(3):470-485. DOI: 10.1002/ana.26712. View

Zesiewicz T, Wilmot G, Kuo S, Perlman S, Greenstein P, Ying S . Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018; 90(10):464-471. PMC: 5863491. DOI: 10.1212/WNL.0000000000005055. View

Reetz K, Dogan I, Hilgers R, Giunti P, Parkinson M, Mariotti C . Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study. Lancet Neurol. 2021; 20(5):362-372. DOI: 10.1016/S1474-4422(21)00027-2. View

Profeta V, McIntyre K, Wells M, Park C, Lynch D . Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia. Expert Opin Investig Drugs. 2023; 32(1):5-16. DOI: 10.1080/13543784.2023.2173063. View

Zwergal A, Feil K, Schniepp R, Strupp M . Cerebellar Dizziness and Vertigo: Etiologies, Diagnostic Assessment, and Treatment. Semin Neurol. 2019; 40(1):87-96. DOI: 10.1055/s-0039-3400315. View

10.

Frei K, Truong D . Medications used to treat tremors. J Neurol Sci. 2022; 435:120194. DOI: 10.1016/j.jns.2022.120194. View

11.

Barbuto S, Kuo S, Winterbottom L, Lee S, Stern Y, Odell M . Home Aerobic Training for Cerebellar Degenerative Diseases: a Randomized Controlled Trial. Cerebellum. 2022; 22(2):272-281. PMC: 8932090. DOI: 10.1007/s12311-022-01394-4. View

12.

Lynch D, Schadt K, Kichula E, McCormack S, Lin K . Friedreich Ataxia: Multidisciplinary Clinical Care. J Multidiscip Healthc. 2021; 14:1645-1658. PMC: 8253929. DOI: 10.2147/JMDH.S292945. View

13.

Shen X, Wu K, Huang Y, Guo Y, Huang S, Zhang Y . Systematic assessment of plasma biomarkers in spinocerebellar ataxia. Neurobiol Dis. 2023; 181:106112. DOI: 10.1016/j.nbd.2023.106112. View

14.

Pfeffer G, Pyle A, Griffin H, Miller J, Wilson V, Turnbull L . SPG7 mutations are a common cause of undiagnosed ataxia. Neurology. 2015; 84(11):1174-6. PMC: 4371411. DOI: 10.1212/WNL.0000000000001369. View

15.

de Silva R, Vallortigara J, Greenfield J, Hunt B, Giunti P, Hadjivassiliou M . Diagnosis and management of progressive ataxia in adults. Pract Neurol. 2019; 19(3):196-207. PMC: 6585307. DOI: 10.1136/practneurol-2018-002096. View

16.

Jacobi H, Tezenas du Montcel S, Bauer P, Giunti P, Cook A, Labrum R . Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurol. 2015; 14(11):1101-8. DOI: 10.1016/S1474-4422(15)00202-1. View

17.

Regner S, Wilcox N, Friedman L, Seyer L, Schadt K, Brigatti K . Friedreich ataxia clinical outcome measures: natural history evaluation in 410 participants. J Child Neurol. 2012; 27(9):1152-8. PMC: 3674496. DOI: 10.1177/0883073812448462. View

18.

Radmard S, Zesiewicz T, Kuo S . Evaluation of Cerebellar Ataxic Patients. Neurol Clin. 2022; 41(1):21-44. PMC: 10354692. DOI: 10.1016/j.ncl.2022.05.002. View

19.

Lynch D, Goldsberry A, Rummey C, Farmer J, Boesch S, Delatycki M . Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data. Ann Clin Transl Neurol. 2023; 11(1):4-16. PMC: 10791025. DOI: 10.1002/acn3.51897. View

20.

Dragasevic-Miskovic N, Stankovic I, Milovanovic A, Kostic V . Autosomal recessive adult onset ataxia. J Neurol. 2021; 269(1):504-533. DOI: 10.1007/s00415-021-10763-8. View